Purpose Iron overload accelerates bone loss in mice lacking the bone morphogenetic protein 6 (Bmp6) gene, which is the key endogenous regulator of hepcidin, iron homeostasis gene. We investigated involvement of other BMPs in preventing haemochromatosis and subsequent osteopenia in Bmp6-/-mice. Methods Iron-treated wild-type (WT) and Bmp6-/-mice were analysed for hepcidin messenger RNA (mRNA) and tissue and blood BMP levels by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), immunohistochemistry, Western blot, enzyme-linked immunosorbent assay (ELISA) and proximity extension assay. BMPs labeled with technetium-99m were used in pharmacokinetic studies. Results In WT mice, 4 h following iron challenge, liver Bmp6 and hepcidin expression were increased, while expression of other Bmps was not affected. In parallel, we provided the first evidence that BMP6 circulates in WT mice and that iron increased the BMP6 serum level and the specific liver uptake of 99m Tc-BMP6. In Bmp6-/-mice, iron challenge led to blunted activation of liver Smad signaling and hepcidin expression with a delay of 24 h, associated with increased Bmp5 M. Pauk : L. Grgurevic : J. Brkljacic : V. Kufner : T. Bordukalo-Niksic :
Introduction
Osteoporosis is a frequent problem in disorders characterised by iron overload, but mechanisms leading to bone loss are not well understood. Recent studies have clearly shown that iron overload accelerates bone loss with decreased bone mineral density (BMD) in patients with haemochromatosis, particularly in the male gender [1, 2] . In addition, in iron-treated mice, an increase in bone resorption and osteoclast number has been found, without a change in osteoblast number and bone-formation parameters [3] . Furthermore, iron overload is associated with osteopenia and osteoporosis, as evidenced in Bmp6-/-mice [4] and in humans. Whether this is caused by a d i r e c t e ff e c t o f i r o n o n b o n e o r m u t a t i o n s i n haemochromatosis-related genes, including Bmp6, remains to be determined.
Systemic iron balance is regulated by the rate of iron entry from the diet and iron release from hepatocyte stores and macrophages, which recycle iron from aged or damaged erythrocytes. Our understanding of the iron metabolism process has advanced in the past decade, mainly as a result of the discovery of hepcidin (Hamp), a key regulator of systemic iron homeostasis [5] . Secreted by the liver, hepcidin induces internalisation and lysosomal degradation of iron exporter ferroportin present on the surface of enterocytes, macrophages and hepatocytes, and thereby inhibits intestinal iron absorption and macrophage iron release [6] . Hepcidin expression is induced by dietary [5] or parenteral [7] iron loading, suggesting its compensatory role in iron homeostasis. Conversely, hepcidin expression is suppressed in conditions of iron deficiency and tissue hypoxia, thus increasing the iron availability for erythrocyte production [8] .
Recent studies have demonstrated a critical role for bone morphogenetic protein (BMP) signaling in regulating hepcidin expression, which involves interaction with the BMP co-receptor, hemojuvelin (HJV) [9, 10] , and translocation of Smad complexes into the nucleus [11, 12] . Support for involvement of the BMP signaling pathway in hepcidin regulation also comes from the observation that the liver-specific Smad4 knockout mouse manifests nearly complete deficiency of hepcidin and a systemic iron overload [13] . Additionally, it has been demonstrated that a loss of Bmp6 function in mice leads to reduced hepatic hepcidin expression and iron overload, suggesting that BMP6 is the key endogenous regulator of hepcidin and iron metabolism [14, 15] . While BMP6 administration increases hepcidin expression and reduces serum iron levels in vivo [16] , BMP inhibitors reduce hepatic hepcidin expression, mobilise reticuloendothelial iron cell stores and increase serum iron [10, 14, 17] .
Although BMP6 is the key endogenous regulator of hepcidin expression and iron metabolism, several studies have shown that other BMPs also stimulate hepcidin expression in vitro [9, 10, 13, 18] . Additionally, recent comparative studies of four hereditary haemochromatosis mouse models, including Bmp6-/-mice, observed the presence of distinct pathways of hepcidin regulation, which raises the possibility of other BMP involvement in iron homeostasis [19] . It is, therefore, unknown whether other BMPs can regulate hepcidin expression in vivo and why they do not fully correct for the iron overload in Bmp6-/-mice, since BMP redundancy has been well documented [20, 21] .
Systemic challenge with iron rapidly induces Smad1/5/8 phosphorylation and Bmp6 and Hamp expression [17, 22] , but the mechanisms by which BMP6 "senses" the iron status is not understood, and whether liver is the exclusive origin of endogenous BMP6 has been debated. Recently, it has been demonstrated that following an iron administration in mice with a 129Sv/Ev background, Bmp6 expression was upregulated in the small intestine [23] . In several subsequent studies, it was suggested that the liver and not the duodenum was the main source of iron-induced Bmp6 expression, either by an iron-enriched diet or by Hfe or Hfe2 expression [24] [25] [26] . Furthermore, it is not known whether BMP6 is the sole mediator of the iron-hepcidin axis.
In this study, we found that iron overload induced hepatic Bmp6 messenger RNA (mRNA), which was accompanied by an increase in circulating BMP6. In the absence of BMP6, iron stimulated hepatic Bmp5 and 7 mRNA and other Bmps in the duodenum, which resulted in a modest and delayed hepcidin expression. Administration of exogenous BMP7 normalised hepcidin expression and corrected bone loss, suggesting that upregulated endogenous BMP7 in Bmp6-/-mice was not sufficient for adequate iron regulation and bone metabolism.
Materials and methods

Animals
Animals were maintained in accordance with the US National Institutes for Health (NIH) Guide for the Care and Use of Laboratory Animals. All experiments were approved by the Institutional Animal Care Review and Ethics Committee, University of Zagreb, School of Medicine. Animals were maintained on standard glucagon-like peptide (GLP) diet (4RF21, Mucedola, Italy; 180 mg/kg iron). For iron treatment experiments, three month-old Bmp6-/-mice with a mixed 129Sv/C57 background (kindly provided by Elizabeth Robertson) [27] and wild-type (WT) mice matched for the background strain (n=5/group; genders were matched between groups) received an i.v. dose of iron-dextran (200 mg iron/kg body weight; ferric hydroxide dextran complex, Sigma-Aldrich). Animals were sacrificed and tissues harvested at four, eight and 24 hours after injection. For measuring BMPs in serum, blood was collected at 12, 24 and 48 hours after iron application. For single BMP-injection experiments, three month-old WT and Bmp6-/-mice received an i.v. injection of BMP7 at 500 μg/kg (n=5/group). Serum and livers were harvested for analysis six hours after injection. In additional experiment, tenweek-old Bmp6-/-mice were ovariectomised (n=14) and 15 days later divided into the following treatment groups: (1) Bmp6-/-+vehicle (n=7); (2) Bmp6-/-+BMP7 (10 μg/kg, 3 times/week; n=7). Sham Bmp6-/-operated mice served as a positive control (n=7). Vehicle injection was prepared as acetate buffer (pH=4.5) with 5 % mannitol. The same buffer has been used for dissolving lyophilised BMP7 (Creative Biomolecules). After four months, these mice were sacrificed. Bone mineral density (BMD) was measured by dual X-ray absortiometry (DXA) (Hologic 600) using the company's small-animal software.
Serum analyses
Serum was analysed for iron concentration and unsaturated ironbinding capacity (UIBC) by standard spectrophotometric method using the Olympus AU2700 (Beckman-Coulter-Olympus).
Production of BMP6 monoclonal antibody BMP6 monoclonal antibody 9 F2 was produced using a standard protocol. In enzyme-linked immunosorbent assay (ELISA), <10 % cross-reactivity with recombinant mature BMP7 was observed.
Immunohistochemical staining
Tissues from Bmp6-/-and WT mice were fixed in 10 % formalin and were paraffin embedded. Sections were cut at 5 μm, deparaffinised in xylene and hydrated in distilled water. Immunocytochemistry was performed using the immunoperoxidase detection system (Zymed, San Francisco, CA, USA). Tissues were incubated with monoclonal BMP6 antibody 9 F2 and hepcidin (56-Z) antibody (1:50; Santa Cruz Biotechnology). BMP7 was detected immunohistochemically as described previously [28] .
Gene-expression analyses
Total RNA was isolated from tissues and primary hepatocytes using TRIzol (Invitrogen). Complementary DNA (cDNA) was generated by reverse-transcription of 1 μg adjusted RNA using Super Script III First-Strand Synthesis System (Invitrogen). Gene expression of interest was measured using a LightCycler FastStart DNA Master SYBR Green kit in a LightCycler instrument (Roche Diagnostics), as described [29] . Results are represented as a fold change in comparative expression level. The list of primers used is shown in Table 1 .
SDS gel electrophoresis and Western blot analyses
Tissues were disrupted with a manual homogeniser in radioimmunoprecipitation assay (RIPA) buffer. Serum (5 μl), duodenum (50 μg) and liver (150 μg) lysates were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to the nitrocellulose membrane. The blots were saturated with 2 % bovine serum albumin (BSA) in Tris-buffered saline containing 0.05 % Tween (TBS-T) and probed overnight at 4°C with primary antibodies against BMP6 (1:400; School of Medicine, Rijeka), BMP9 (1:1000; R&D Systems), phosphorylated Smad1/5/8 (1:1000; Cell Signaling), Smad1/5/8 (1:200; Santa Cruz Biotechnology) or β-actin (1:1000; Millipore). Immunolabeling was detected using alkaline phosphatase-conjugated secondary antibodies and 5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium chloride (BCIP/NBT) substrate (Sigma), and the proteins were quantified using ImageJ software (NIH). Results are presented as the mean of duplicates.
Mass spectrometry
After Coomassie staining, each gel lane was sliced into 15 pieces and the corresponding pieces combined. The pieces were then subjected to in-gel reduction, alkylation and trypsin digestion. Tryptic peptides were analysed by liquid chromatography-mass spectrometry (LC-MS). Easy-nLC nanoflow high-performance liquid chromatography (HPLC) system (Proxeon Biosystems) was coupled to an LTQOrbitrap mass spectrometer (Thermo Scientific) using a nanoelectrospray LC-MS interface (Proxeon Biosystems). Peptides were loaded on a home-made 75 μm C18 HPLC column in solvent "A" (0.5 % acetic acid in Milli-Q water) and eluted with a 70minute segmented linear gradient of 10-60 % solvent "B" (80 % acetonitrile, 0.5 % acetic acid in Milli-Q water) at a flow rate of 250 nL/min, as described [30] .
Serum measurement of BMP6, BMP7 and BMP9 Serum samples were tested for BMP7 and BMP9 using BMP7 ELISA kit [31] (R&D Systems) and BMP9 ELISA kit [32] (AdipoBiosciences), according to the manufacturer's instructions. For sensitive BMP6 detection and quantification, we employed the proximity extension assay technology using the Proseek assay development kit (Olink Bioscience). Mouse BMP6 antibodies (AF6325; R&D Systems), which showed ∼5 % cross-reactivity with recombinant mouse BMP5 and BMP7, were conjugated with a pair of DNA oligonucleotides, and upon binding to the target protein in 1 μl of serum sample, a DNA duplex formed and was extended in real-time PCR, according to the manual's instructions. Tc-BMP6 and used similarly. Blood and organs were isolated, and radioactivity was measured in a gamma counter and expressed as a percentage (%) of the applied dose in counts per minute (cpm). All values were corrected for the half-life of 99m technetium.
Data analyses
Results are reported as mean± standard error of the mean (SEM). Changes in gene expression and serum parameters were evaluated using the two-tailed Student's t test. Results were considered significant when P was<0.05.
Results
99m
Tc-BMP6 accumulated in liver following iron administration Four hours after iron administration, Bmp6 expression in the liver was increased by 4.7-fold (Fig. 1a) , accompanied by an increase in hepatic hepcidin mRNA by 4.9-fold (Fig. 1b) . In the duodenum, in parallel, Bmp6 mRNA expression was decreased following iron injection, while in the jejunum it was unchanged (Fig. 1a) . This was confirmed by immunohistochemistry using an antibody raised against the mature domain of BMP6 (Fig. 1c, i , ii) and against hepcidin (Fig. 1c, iv,  v) . BMP6 was previously shown to be restricted to nonparenchymal liver cells (stellate and Kupffer cells) [33] . However, we found that BMP6 localisation in iron-loaded livers was dominantly in hepatocytes of the liver acini periportal zone, which was not observed in Bmp6-/-mice (Fig. 1d) . To further explore whether iron affects the biodistribution of BMP6, and to confirm hepatic source of BMP6, we developed a procedure of labeling BMP6 with 99m technetium ( 99m Tc-BMP6) using the Isolink labeling kit. BMP6 structure and function were well maintained following labeling, as evidenced by gel electrophoresis and Western blot of 99m Tc-BMP6, as well as the activity of a BMP-responsive Tc-BMP6 concomitantly administered with iron to rats, predominantly accumulated in the liver at 3 h following an iron injection, while its uptake by the duodenum, jejunum, kidney and blood was similar to control animals (Fig. 1e) . To determine whether accumulation in the liver was specific for BMP6, we used 99m Tc labeled BMP7 and found similar results in iron loaded and control animals (data not shown).
BMP6 circulated in serum and correlated with induced iron overload in WT mice
Recently published data suggested that in WT mice, iron significantly increased BMP6 in serum, represented as a 23-kDa band by Western blot analysis using the Santa Cruz S-20 anti-BMP6 antibody [23] . However, this antibody was shown to be nonspecific for mouse BMP6 in Western blot experiments, as the 23-kDa band was also observed in Bmp6-/-mice [24] . Under similar experimental conditions, using LC-MS, we detected no BMP6 in the total serum sample of iron-loaded mice. Moreover, the 23-kDa band detected by a Coomassie staining contained no BMPs, but we found several unrelated proteins, predominantly retinol-binding protein 4 (Rbp4) and apolipoprotein M (apoM) (Fig. 2a) .
In order to determine whether BMP6 circulates, we analysed biological fluids of mice and humans using the human BMP6 DuoSet ELISA (R&D Systems), but we failed to detect BMP6 in serum (data not shown). To enhance assay sensitivity and simplify the BMP6 measurement procedure, we developed an alternative assay, the proximity extension assay (PEA), which is reported to measure protein levels from 0.01 to 10 000 pM (Olink Bioscience). Our results indicated that the lower detection limit or sensitivity of the assay was 10 pg/ml, as this is the concentration of two standard deviations (SDs) above the background. For BMP6 detection, we used mouse BMP6 antibodies (R&D Systems) and determined that BMP6 circulates at 55.46±9.8 pg/ml in only 1 μl of mouse serum. Iron challenge, as measured by PEA, increased circulating levels of BMP6 in WT mice at 12 h to 109.96±25.4 and at 24 h to 128.7±21 pg/ml (Fig. 2b) . The background level in Bmp6-/-mice was in the range of 5-10 % of control values in WT mice (data not shown).
Iron injection resulted in delayed Smad 1/5/8 signaling and hepcidin response in Bmp6-/-mice We next tested the effects of an iron overload on the temporal dynamics of hepcidin expression in Bmp6-/-mice relative to WT control mice. In Bmp6-/-mice, liver Hamp mRNA induction by iron was delayed and dampened compared with in WT mice. There was a trend toward increased Hamp mRNA expression by 2-fold at 8 h and 4.3-fold at 24 h after iron injection, as demonstrated by qPCR (Fig. 3a) and immunohistochemical staining (Fig. 3b) .
As BMP signaling has been shown to induce hepcidin expression, we tested whether phosphorylation of Smad 1/5/ 8 was modulated in the liver extract of iron-challenged Bmp6-/ -mice. At 24 hours, iron increased Smad 1/5/8 phosphorylation 1.9-fold in liver lysates of Bmp6-/-mice (Fig. 3c) , suggesting that other BMPs were activated to stimulate liver Smad signaling; however, it was insufficient for an appropriate Hamp response.
Iron administration affected BMPs in liver, duodenum and circulation in Bmp6-/-mice Next, we investigated the expression of other BMPs and their potential roles in hepcidin regulation. Bmp2, 4, 5, 7 and 9 transcripts were unchanged in the liver and duodenum of WT mice during eight hours following iron injection, except for decreased Bmp2 in the duodenum (Fig. 4a-e) .
Conversely, in Bmp6-/-mice, iron time-dependently increased Bmp2, 4, 5, and 9 expression in the duodenum (Fig. 5a-d) . In the liver, Bmp5 mRNA was slightly increased at 24 hours after iron administration in Bmp6-/-mice (Fig. 5c) . As BMP9 has been previously claimed to circulate [26], we measured its serum level and found in Bmp6-/-mice an increased serum BMP9 concentration at 24 hours following iron administration (Fig. 5e) . Furthermore, immunoblot analyses confirmed that at 12 h, BMP9 protein was increased in the duodenum of Bmp6-/-mice and decreased at 24 h (Fig. 5f ). This suggested that BMP9 from the gut might have been released into the blood as an attempt by the duodenum to contribute to preventing iron overload caused by the lack of BMP6.
Liver Bmp7 expression was, however, increased by 3.8-fold at four hours (Fig. 6a ) and 3.27-fold at 8 h (not shown), which was also verified by BMP7 immunostaining of liver sections (Fig. 6b) . Together, these data suggested that in the liver of Bmp6-/-mice, Bmp7 was upregulated at an early time point and Bmp5 at a later time point after iron injection, while Bmp2, 4, 5 and 9 were time-dependently increased in the duodenum. However, these compensatory mechanisms in Bmp6-/-mice were not sufficient to invoke an adequate BMP-dependent defense against iron overload to prevent hemochromatosis.
Exogenous BMP7 increased hepcidin expression, reduced iron accumulation and corrected for bone loss in WT and Bmp6-/-mice We previously showed that BMP6 administration increases hepatic Hamp mRNA expression and reduces serum iron in a dose-dependent manner [14] . To examine a potential of exogenous BMP7 administration on hepcidin expression and plasma iron distribution, WT and Bmp6-/-mice were treated i.v. with BMP7. Indeed, BMP7 significantly increased the liver Hamp mRNA by 20-fold and reduced the serum iron level in Bmp6-/-mice at six hours ( Fig. 7a and b) , which was verified by hepcidin immunohistochemistry of liver sections (Fig. 7c) . Interestingly, in WT mice, the induction of hepcidin expression and the reduction of serum iron following BMP7 injection were modest compared with Bmp6-/-mice. However, as Bmp6-/-mice contain much less hepcidin, immunohistochemical analyses of the liver showed only moderate increase in hepcidin staining in Bmp6-/-mice compared with WT mice. The induction of liver Smad1/5/8 phosphorylation by BMP7 in Bmp6-/-mice was also significant, mirroring the hepcidin response (Fig. 7d) . Thus, exogenous BMP7 ameliorated hepcidin deficiency in Bmp6-/-mice, suggesting that these animals were primed to respond to compensatory regulation by endogenous BMPs, which were, however, too low to adequately upregulate hepcidin and prevent hemochromatosis. In addition, i.v. therapy with BMP7 (10 μg/kg) for fourmonths significantly increased bone volume in ovariectomised Bmp6-/-mice (Fig. 8) .
Discussion
Endogenous BMP6 increases hepcidin expression and reduces the serum iron in mice, and has a key role in the iron metabolism [14, 15] . Recently, it has been suggested that epithelial cells of the small intestine are the main source of BMP6 upon "sensing" iron in vivo and that enterocytes produce and release BMP6 into the circulation to reach the liver and regulate hepcidin expression [23] . In contrast, we and others [24, 25] have shown that iron increased the hepatic Bmp6 expression in WT mice without affecting its expression in the duodenum or jejunum. We were, however, not able to detect BMP6 in serum (5 μl) by LC-MS analyses as have been previously suggested [23] . Indeed, we demonstrated that the ∼23-kDa band, previously reported, detected by Western blot [23] did not contain BMP6. Furthermore, using the DuoSet ELISA (R&D Systems), we could not detect BMP6 in Fig. 2 Iron increased bone morphogenic protein 6 (BMP6) circulating levels in wild-type (WT) mice. Serum samples of mice loaded with iron were submitted to sulfate polyacrylamide gel electrophoresis (SDS) gel electrophoresis, after which each protein band was analysed by a liquid chromatography-mass spectrometry (LC-MS), including the 23-kDa band previously identified as a mature BMP6 [23] . For BMP6 quantification, serum was collected at zero, 12 and 24 hours following iron injection and measured in b the proximity extension assay (*P=0.01 compared with time zero and 0.038 compared with 24hour control). Results are reported as mean ± standard error of the mean(SEM). Exact P values are shown Fig. 3 Bmp6-/-mice showed delayed hepcidin response and Smad 1/5/8 signaling to iron loading. Three-month-old Bmp6-/ -mice were treated with irondextran and killed at zero, four, eight and 24 hours following injection (n=5/group). Liver tissues were analysed for hepatic a Hamp relative to Gapdh messenger RNA (mRNA) by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), b immunohistochemical staining with hepcidin antibodies (original magnification×20) and c hepatic phosphorylated Smad 1/5/8 relative to Smad 1/5/8 protein level by Western blot at four, eight and 24 hours following iron injection. Results are reported as the mean ± standard error of the mean (SEM). Exact P values are shown biological fluids of mice and humans. Therefore, we developed a BMP6 proximity extension assay (PEA), which enabled us to analyse BMP6 in 1-μl serum samples before and following iron exposure. We showed that BMP6 circulates in the serum, and this is the first demonstration of a physiological range of circulating BMP6. Furthermore, we found that iron loading was followed by a BMP6 increase in mouse serum, indicating that circulating levels of BMP6 may reflect bodily iron status. Interestingly, in untreated mice, BMP6 concentrations displayed a diurnal variation, with concentrations being lowest in the morning and increasing throughout the day before declining during evening hours. Given the already known hepcidin diurnal rhythm [34] , our results suggest that hepcidin variations might reflect the BMP6 circulating pattern. Our further goal is to determine the range of circulating BMP6 in healthy individuals and patients with osteoporosis and search for any discrepancies. Iron loading was also followed by a pronounced increase of hepatic Bmp6 mRNA and protein, as well as hepcidin mRNA, indicating a major role for hepatic BMP6 in protecting the organism against iron. Consistent with this, the biodistribution of i.v. injected 99m Tc-BMP6 showed a higher liver uptake of BMP6 in the presence of iron compared with a lesser uptake in the liver of 99m Tc-BMP7.
To assess other potential mediators in iron homeostasis, we analysed hepcidin response to iron in Bmp6-/-mice. Twentyfour hours following iron injection, hepcidin expression was increased in the liver but failed to reach levels seen in WT mice. Also, iron injection caused hepatic Smad1/5/8 activation, which led to the hypothesis that BMPs, other than BMP6, were activated to mediate hepcidin expression in response to iron, although at an insufficient level. Similar modulation of hepcidin mRNA has been previously reported in Bmp6-/-mice at the 21st day of chronic iron loading [19] . These results suggest that in response to iron, increased hepcidin in Bmp6-/ -mice could be regulated via other pathways. Indeed, in Bmp6-/-mice, we showed a time-dependent increase of Bmp2, 4, 5 and 9 mRNA in the duodenum following iron injection. In addition, increased duodenal Bmp9 expression was accompanied by increased serum Fig. 5 Iron increased expression of bone morphogenic protein (BMP) Bmp2, 4, 5 and 9 in duodenum of Bmp6-/-mice. Threemonth-old Bmp6-/-mice were treated i.v. with iron-dextran at 200 mg/kg and were killed at zero, four and 24 hours after injection (n=5/group). Tissues were analysed for a Bmp2, b Bmp4, c Bmp5 and d Bmp9 relative to Gapdh messenger RNA (mRNA) by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). e BMP9 serum levels were measured with commercial BMP9 enzyme-linked immunosorbent assay (ELISA) at several time points between zero and 24 hours after iron injection (*P= 0.04 compared with zero points, and 0.007 compared with 24hours control) and f BMP9 relative to β-actin expression by Western blot at 12 and 24 hours following iron overload in the duodenum. Results are reported as mean ± standard error of the mean(SEM). Exact P values are shown Fig. 6 Iron induced bone morphogenic protein (BMP) Bmp7 expression in the liver of Bmp6-/-mice. Three-month-old Bmp6-/-mice were treated i.v. with iron-dextran at 200 mg/kg and were killed at zero, four and 24 hours after injection (n=5/group). Tissues were analysed for a Bmp7 relative to Gapdh messenger RNA (mRNA) by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), b hepatic BMP7 staining (original magnification×20). Results are reported as the mean ± standard error of the mean(SEM). Exact P values are shown BMP9, suggesting that BMP9 might have been released from the gut into the circulation. Previous studies demonstrated that BMP2, 4 and 5 can all bind to hemojuvelin, the BMP coreceptor that plays an essential role in hepcidin regulation and iron homeostasis [9] , with high affinity (K D 's 4.5-17 nM) [35] . Moreover, BMP2, 4, 5 and 9 can all stimulate hepcidin expression in vitro, and BMP2 can stimulate hepcidin expression in vivo [10, 18] . Notably, duodenal expression of BMPs was not upregulated by a single injection of iron in WT mice, suggesting that a functional role, if any, for these duodenal BMPs in hepcidin regulation and systemic iron homeostasis may be limited to pathologic conditions or more prolonged iron exposure. Future studies are needed to continue exploring the role of endogenous circulating BMP9 and other duodenal upregulated BMPs in hepcidin regulation and iron homeostasis in Bmp6-/-mice and other conditions.
In the liver of Bmp6-/-mice, we found a moderately increased expression of Bmp5 at 24 hours and more significant increase of Bmp7 at four and eight hours after an iron injection. Interestingly, iron injection also caused a trend toward increased liver Bmp5 expression in WT mice but did not affect liver Bmp7 expression. Although BMP7 is predominantly produced in the kidney and bone [36] , hepatocytes have also been recognised as a source of BMP7 [31, 37] , albeit Fig. 7 Exogenous bone morphogenic protein (BMP)7 increases hepcidin expression and reduces serum iron in wild-type (WT) and Bmp6-/-mice. Threemonth-old WT Bmp6-/-mice received an i.v. injection of BMP7 at 500 μg/kg; six hours later, blood and liver were harvested (n=5/group). Tissues were analysed for a hepatic Hamp relative to Gapdh messenger RNA (mRNA) by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), b serum iron, c hepatic immunohistochemical staining with hepcidin antibodies (original magnification×20) and d hepatic phosphorylated Smad 1/5/8 relative to Smad 1/5/8 protein level by Western blot six hours following BMP7 injection in WT and Bmp6-/-mice. Results are reported as mean±standard error of the mean (SEM). Exact P values are shown Fig. 8 Treatment of bone morphogenic protein (BMP) Bmp6-/-mice with BMP7 (10 μg/kg) restored bone loss following ovariectomy. Bmp6-/ -mice were ovariectomised (n=14) at ten weeks of age and were treated 15 days later with BMP7 (10 μg/kg, three times/week) for four months (n=7). Femoral bone mineral density (BMD) values were compared with ovariectomised (n=7) and sham Bmp6-/-mice (n=7). Results are reported as mean±standard error of the mean (SEM). Exact P values are shown with low basal levels. BMP7 has also been demonstrated to bind to hemojuvelin with high affinity (K D 20nM) [35] and to stimulate hepcidin expression in vitro [10] . To determine the BMP7 effect on hepcidin expression in vivo, we treated WT and Bmp6-/-mice with exogenous BMP7, which induced hepcidin expression and Smad 1/5/8 phosphorylation. The more robust response of Bmp6-/-mice compared with WT animals to exogenous BMP7 suggests an adaptation to BMP6 loss by increasing sensitivity to BMP7, but the exact mechanism should be further explored. In addition, systemically applied BMP7 to ovariectomised Bmp6 -/-mice increased bone volume and restored bone microarchitecture and skeletal quality.
These results support an alternative mechanism for hepcidin regulation in Bmp6-/-mice, which involves BMPs other than BMP6. However, although an exogenous dose of BMP7 in Bmp6-/-mice resulted in an increased bone volume and hepcidin expression, which reached levels of those from WT mice, the lack of an early hepcidin response after iron injection in Bmp6-/-mice was presumably due to an insufficient endogenous amount of BMP required to substitute for BMP6. BMP6 is an essential, but not exclusive, endogenous regulator of hepcidin in preventing hemochromatosis in Bmp6-/-mice.
